申请人:Queen's University at Kingston
公开号:US20200323829A1
公开(公告)日:2020-10-15
Pharmaceutical compositions that include inhibitors of mitochondrial fission are described for the treatment and/or mitigation of cancer, pulmonary arterial hypertension, cardioprotection, stroke, coronary heart disease, neurological disorder, a neurodegenerative disease, Parksinonism, Huntington's Chorea, Alzheimer's disease, diabetic cardiomyopathy, fatty liver diseases, non-alcoholic fatty liver diseases, or alcohol-related liver disease.
描述了包括线粒体分裂抑制剂的药物组合物,用于治疗和/或缓解癌症、肺动脉高压、心脏保护、中风、冠心病、神经紊乱、神经退行性疾病、帕金森病、亨廷顿舞蹈症、阿尔茨海默病、糖尿病心肌病、脂肪肝病、非酒精性脂肪肝病或与酒精相关的肝病。